Advertisement

Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      As compared to normolipoproteinemic controls 10 male subjects with primary type IV hyperlipoproteinemia had higher apolipoprotein E and lower apolipoprotein C-II concentrations in the very low density lipoprotein (VLDL) fraction. After 8 weeks of treatment with 0.6. g/day bezafibrate, cholesterol and triglyceride in the serum and VLDL were significantly lower. The decrease of VLDL lipids was accompanied by a significant decrease of the apolipoproteins and of the lipid/protein ratio in VLDL. The analysis of the soluble VLDL apolipoproteins revealed a decrease of apo E and an increase of apo C1 and apo C2, resulting in a decrease of the apo E/apo C ratio.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Olsson A.G.
        • Rössner S.
        • Walldius G.
        • Carlson L.A.
        • Lang P.D.
        Effect of BM-15075 on lipoprotein concentrations in different types of hyperlipoproteinemia.
        Atherosclerosis. 1977; 27: 279
        • Weisweiler P.
        • Schwandt P.
        Lipoprotein lipids and apolipoproteins after six months' treatment with bezafibrate.
        Artery. 1980; 5: 402
        • Schwandt P.
        • Weisweiler P.
        Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
        Artery. 1980; 7: 464
        • Klose G.
        • Behrendt J.
        • Vollmar J.
        • Greten H.
        Wirkung von Bezafibrat auf die Lipoprotein-lipasenaktivität and die Leber-Triglyceridhydrolase bei gesunden Versuchspersonen.
        in: Greten H. Lang P.D. Schettler G. Lipoproteine and Herzinfarkt. Verlag G. Witzstrock, Baden-Baden, Köln, New York1979: 185
        • Eisenberg S.
        Very-low-density lipoprotein metabolism.
        Progr. Biochem. Pharmacol. 1979; 15: 139
        • Ganesan D.
        • Bass H.B.
        • McConathy W.J.
        • Alaupovic P.
        Is decreased activity of C-II activated lipoprotein lipase in type III hyperlipoproteinemia (broad-β-disease) a cause or an effect of increased apolipoprotein E levels?.
        Metabolism. 1976; 35: 1189
        • Breckenridge W.C.
        • Little J.A.
        • Steiner G.
        • Chow A.
        • Poapst M.
        Hypertriglyceridemia associated with deficiency of apolipoprotein C-II.
        N. Engl. J. Med. 1978; 298: 1265
        • La Rosa J.C.
        • Levy R.I.
        • Herbert P.
        • Lux S.E.
        • Fredrickson D.S.
        A specific apoprotein activator for lipoprotein lipase.
        Biochem. Biophys. Res. Comm. 1972; 41: 57
        • Brown W.V.
        • Baginsky M.L.
        Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoproteins.
        Biochem. Biophys. Res. Comm. 1972; 46: 375
        • Innerarity T.L.
        • Mahley R.W.
        Enhanced binding by cultured human fibroblasts of apo- E containing lipoproteins as compared with low-density lipoproteins.
        Biochemistry. 1978; 17: 1440
        • Kashyap M.L.
        • Srivastava L.S.
        • Chen C.Y.
        • Perisutti G.
        • Campbell M.
        • Lutmer R.F.
        • Glueck C.J.
        Radioimmunoassay of human apolipoprotein C II.
        J. Clin. Invest. 1977; 60: 171
        • Carlson L.A.
        • Ballantyne D.
        Changing relative content of apolipoproteins C-II, and C-III of very low density lipoproteins in hypertriglyceridemia.
        Atherosclerosis. 1976; 23: 563
        • Catapano A.L.
        The distribution of apo C-II and apo C-III in very low density lipoproteins of normal and type IV subjects.
        Atherosclerosis. 1980; 35: 419
        • Drosner M.
        • Weisweiler P.
        • Schwandt P.
        Changes of the VLDL-apolipoproteins C in primary type IV-hyperlipoproteinaemia by bezafibrate.
        J. Clin. Chem. Clin. Biochem. 1980; 18 (Abstract): 5.18
        • Beaumont J.-L.
        • Carlson L.A.
        • Cooper G.R.
        • Fejfar Z.
        • Fredrickson D.S.
        • Strasser T.
        Classification of hyperlipidemias and hyperlipoproteinemias.
        Bull. Wld Hlth Org. 1970; 43: 891
        • Schwandt P.
        • Weisweiler P.
        The effect of D-thyroxine on lipoprotein lipids and apolipoproteins in primary type IIa hyperlipoproteinemia.
        Atherosclerosis. 1980; 35: 301
        • Kane J.P.
        • Sata T.
        • Hamilton R.L.
        • Havel R.J.
        Apoprotein composition of very low density lipoproteins of human serum.
        J. Clin. Invest. 1975; 56: 1622
        • Naruszwicz M.
        • Szostak W.B.
        • Cybulska B.
        • Kotlowska M.
        • Chotlowska E.
        The influence of clofibrate on lipid and protein components of very low-density lipoproteins in type IV-hyperlipoproteinemia.
        Atherosclerosis. 1980; 35: 383
        • Schonfeld G.
        • Weidman S.W.
        • Witztum J.L.
        • Bowen R.M.
        Alterations in levels and interrelations of plasma apolipoproteins induced by diet.
        Metabolism. 1976; 25: 261
        • Pagnan A.
        • Casara D.
        • Zanetti G.
        • Guarini P.
        • Graggion M.
        Serum lipids, “double pre-beta lipoproteinemia”, and distribution of the apo-very-low-density (VLDL) lipoprotein peptides in hypothyroid patients before and after substitution therapy.
        Metabolism. 1980; 29: 1026